Maciej Banach: Navigating Therapeutic Complexity in Cardiometabolic Disease Prevention
Maciej Banach, Chief Medical Officer at Graylight Imaging, Visiting Senior Research Fellow at Liverpool Centre for Cardiovascular Science, Adjunct Professor at The Johns Hopkins University School of Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Progress in Cardiovascular Diseases, adding:
“See our recent paper on a critically important topic: how to deliver effective CVD prevention for patients with multimorbidity and multiple concurrent risk factors, each often requiring several interventions or medications (oral, subcutaneous) with different dosing schedules.
In other words: how can we achieve effective, patient-centered CVD prevention overall after successfully managing individual risk factors?
‘The goal of modern cardiometabolic medicine should be maximal clinical benefit through minimal therapeutic friction (complex regimens, side-effects, monitoring requirements, adherence, high costs, limited access, etc.).
Only by aligning our rapid pace of innovation with the pragmatic constraints of real world care can we ensure that the ‘era of polypharmacy’ leads to better outcomes rather than just more prescriptions.'”
Title: Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies
Authors: Yashendra Sethi, Kunal Mahajan, Michael D. Shapiro, Maciej Banach
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 8, 2026, 04:10Rutendo Muzambi: Hospital Admission Patterns and Care Disparities in Sickle Cell Disease
-
Oct 8, 2026, 03:50Olfat Berro: Redefining the Future of Haemophilia A
-
Oct 8, 2026, 03:35Tasnia Tarana: Heavy Menstrual Bleeding When the Cause Is Not in the Uterus
-
Oct 8, 2026, 03:28Kian Haseli: Electrophysiological PIEZO1 Analysis Advances Diagnosis in Hereditary Xerocytosis
-
Oct 8, 2026, 03:20Sthanu Subramanian: Leukopenia in Sepsis A Marker of Severe Disease
-
Oct 7, 2026, 16:44Amor Salah: 2026 NCS/SCCM Guidelines for Managing Antithrombotic-Associated ICH
-
Oct 7, 2026, 16:04NETs in Thrombosis: From Mechanism to Therapeutic Target
-
Oct 7, 2026, 15:28Amir Samimi: Prognostic Value of Platelet Count in Resected HNSCC
-
Oct 7, 2026, 15:21Eloïse Laouenan: Bridging Immunity and Thrombosis in MVTE